| 1  | Using Deep learning to Predict Cardiovascular Magnetic Resonance Findings from  |  |  |
|----|---|--|--|
| 2  | Echocardiography Videos   |  |  |
| 3  |   |  |  |
| 4  | Short title: Deep learning prediction of CMR from echocardiography  |  |  |
| 5  | Authors and affiliations:   |  |  |
| 6  | Yuki Sahashi MD, <sup>1</sup> MSc; Milos Vukadinovic, <sup>1,3</sup> BS; Grant Duffy, BS; <sup>1</sup> Debiao Li,           |  |  |
| 7  | PhD; <sup>3</sup> Susan Cheng, MD; <sup>1</sup> Daniel S. Berman, MD; <sup>4</sup> David Ouyang MD*; <sup>1,2</sup> Alan C. |  |  |
| 8  | Kwan MD* <sup>1</sup>   |  |  |
| 9  |   |  |  |
| 10 | *Co-Senior Author   |  |  |
| 11 | 1. Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center,  |  |  |
| 12 | Los Angeles, CA   |  |  |
| 13 | 2. Division of Artificial Intelligence in Medicine, Cedars-Sinai Medical Center,  |  |  |
| 14 | Los Angeles, CA   |  |  |
| 15 | 3. Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los  |  |  |
| 16 | Angeles, CA   |  |  |
| 17 | 4. Department of Imaging and Medicine, Cedars-Sinai Medical Center, Los   |  |  |
| 18 | Angeles, CA   |  |  |
| 19 | Correspondence: alan.kwan@cshs.org, David.ouyang@cshs.org   |  |  |
| 20 | 127 S. San Vicente Blvd, AHSP A3600   |  |  |
| 21 | Los Angeles, CA 90048   |  |  |
| 22 | Word Count: 279 words (Abstract) / 2403 words (Main body)   |  |  |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 23 ABSTRACT

24

### 25 Background

26 Echocardiography is the most common modality for assessing cardiac structure and 27 function. While cardiac magnetic resonance (CMR) imaging is less accessible, CMR 28 can provide unique tissue characterization including late gadolinium enhancement (LGE), T1 and T2 mapping, and extracellular volume (ECV) which are associated with 29 tissue fibrosis, infiltration, and inflammation. While deep learning has been shown to 30 uncover findings not recognized by clinicians, it is unknown whether CMR-based tissue 31 32 characteristics can be derived from echocardiography videos using deep learning. We hypothesized that deep learning applied to echocardiography could predict CMR-based 33 34 measurements.

35

#### 36 Methods

In a retrospective single-center study, adult patients with CMRs and echocardiography studies within 30 days were included. A video-based convolutional neural network was trained on echocardiography videos to predict CMR-derived labels including wall motion abnormality (WMA) presence, LGE presence, and abnormal T1, T2 or ECV across echocardiography views. The model performance was evaluated in a held-out test dataset not used for training.

43

### 44 **Results**

The study population included 1,453 adult patients (mean age 56±18 years, 42% female) with 2,556 paired echocardiography studies occurring on average 2 days after

CMR (interquartile range 2 days prior to 6 days after). The model had high predictive
capability for presence of WMA (AUC 0.873 [95%CI 0.816-0.922]), however, the
model was unable to reliably detect the presence of LGE (AUC 0.699 [0.613-0.780]),
native T1 (AUC 0.614 [0.500-0.715]), T2 0.553 [0.420-0.692], or ECV 0.564
[0.455-0.691]).

52

#### 53 Conclusions

54 Deep learning applied to echocardiography accurately identified CMR-based WMA, but 55 was unable to predict tissue characteristics, suggesting that signal for these tissue 56 characteristics may not be present within ultrasound videos, and that the use of CMR for 57 tissue characterization remains essential within cardiology.

58

59

### 60 Clinical Perspective:

61 Tissue characterization of the heart muscle is useful for clinical diagnosis and prognosis 62 by identifying myocardial fibrosis, inflammation, and infiltration, and can be measured using cardiac MRI. While echocardiography is highly accessible and provides excellent 63 functional information, its ability to provide tissue characterization information is 64 limited at this time. Our study using a deep learning approach to predict cardiac 65 MRI-based tissue characteristics from echocardiography showed limited ability to do so, 66 suggesting that alternative approaches, including non-deep learning methods should be 67 considered in future research. 68

69

- 71 Keywords: Cardiac magnetic resonance imaging, Echocardiogram, Deep learning,
- 72 Convolutional neural network
- 73

74 Abbreviations:

- 75 AHA: American Heart Association
- 76 AUROC: Area under receiver operating characteristic
- 77 A4C: Apical 4 chamber
- 78 A2C: Apical 2 chamber
- 79 CMR: Cardiac magnetic resonance
- 80 ECV: Extracellular volume
- 81 LVEF: Left ventricular ejection fraction
- 82 LGE: late gadolinium enhancement
- 83 PLAX: Parasternal long axis
- 84 MOLLI: modified inversion look-locker

### 86 Introduction

87

Echocardiography plays a central role within cardiovascular care, providing essential 88 information on cardiac structure and function in a highly-accessible format<sup>1 2</sup>. Cardiac 89 90 MRI (CMR) is also critical to cardiovascular care but has reduced accessibility due to 91 the availability of scanners and qualified physicians to interpret the images. In addition to providing information on cardiac structure and function, CMR is able to provide 92 unique tissue characterization that is helpful for assessing for etiology of disease<sup>3</sup>. This 93 includes myocardial composition including scarring through late gadolinium 94 95 enhancement (LGE) and infiltration, edema, and diffuse fibrosis through relaxometry techniques such as T1 and T2 mapping, and extracellular volume (ECV) fraction. 96 Despite the utility of CMR<sup>4</sup>, logistical barriers continue to limit its broader uptake, 97 including the availability of CMR resources, the examination cost, the use of 98 99 gadolinium contrast, and logistical complexity.

100

Deep learning applied to medical imaging provides the opportunity to obtain more 101 information than currently recognized by clinicians in standard clinical care<sup>5–9</sup>. For 102 103 example, deep learning applied to echocardiography has been shown to identify hidden 104 features invisible to the human eye such as age, gender, serological biomarkers, 105 prognosis, and tissue characteristics of cardiac amyloidosis and hypertrophic cardiomyopathy<sup>10,11</sup>. We hypothesized that deep learning applied to echocardiography 106 could predict CMR-based measurements. In this study, we train a video-based 107 108 convolutional neural network to predict CMR features from patients with paired CMR and echocardiography studies. Predicted CMR characteristics including wall motion 109

abnormalities, myocardial scar, and markers of tissue infiltration, edema, and diffuse

111 fibrosis were assessed for deep learning evaluation.

#### 113 Methods

114

### 115 Data and study population

We identified all adults aged over 18 years at a large cardiac quaternary care center who 116 117 received clinical CMR, with at least one clinical transthoracic echocardiogram within 30 118 days of the CMR between May 2011 and June 2022. All echocardiography were performed using Philips EPIQ 7 or iE33 ultrasound machines. Echocardiography views 119 120 including apical four-chamber (A4c), apical two-chamber (A2c), and parasternal long axis (PLAX), were automatically extracted using an automated view classifier. Videos 121 122 underwent automated image preprocessing including removing identifying information, electrocardiogram and respirometer tracings, and cropping and downsampling images 123 using cubic interpolation to a standard size and resolution of  $112 \times 112$ -pixels<sup>12</sup>. This 124 125 study was approved by the Institutional Review Board at Cedars-Sinai Medical Center 126 and informed consent was waived due to the retrospective analysis.

127

128 Echocardiography studies were paired with the nearest CMR study within 30 days. Deep learning models were trained on echocardiogram videos with labels derived from 129 130 the clincal report of the temporally closest CMR if a single echocardiography study had 131 multiple CMRs within 30 days. Labels included presence or absence of wall motion 132 abnormalities within the given echocardiography view (e.g., within AHA segments included within an apical 4-chamber view versus 2-chamber versus parasternal long 133 axis) or globally (within any segment), presence or absence of LGE within a given view 134 or globally, and both continuous and dichotomized measures of T1, T2, and ECV. 135 Dichotomization was based on abnormal values of native T1 times over 1060ms, T2 136

| 37  | times over 58ms, and ECV values above 33%, appropriate to scanner vendor and                                      |
|-----|---|
| 38  | strength and based on local practice and published values <sup>13</sup> <sup>14</sup> . Overall study pipeline is |
| 139 | demonstrated in the Graphical Abstract.   |
| 40  |   |
| 41  |   |
| 42  | CMR protocol and assessment   |
| 43  | All CMR examinations were clinically-ordered studies performed using a 1.5T Avanto                                |
| 44  | scanner (Siemens Healthineers, Erlangen, Germany). While clinical protocols varied                                |
| 45  | over time, cine SSFP images were graded at the time of acquisition for the presence or                            |
| 46  | absence of regional wall motion abnormalities based on an American Heart Association                              |
| 47  | (AHA) 17 segmentation model <sup>15</sup> . If available, T1 mapping was performed using a                        |
| 48  | standard 5(3)3 modified inversion look-locker (MOLLI) sequence, with measurement                                  |
| 49  | of the T1 value within the mid-sepum within the mid slice. If overt tissue abnormalities                          |
| 50  | were present in this region, measurement representative of the diffuse tissue                                     |
| 51  | composition would be performed in a secondary region, most commonly basal   |
| 52  | mid-septal slice, consistent with guidelines. If available, T2 mapping was performed                              |
| 53  | using a T2-prepped SSFP sequence, with similar measurement approach as used for T1                                |
| 54  | values. Post-contrast images included T1-mapping using a short-T1 optimized MOLLI                                 |
| 55  | approach. ECV values were calculated from the pre- and post-contrast T1 maps in                                   |
| 56  | combination with point-of-care hematocrit masurement. LGE was measured 12-20                                      |
| 57  | min after gadolinium contrast injection (Gadbutrol), using turbo FLASH or magnitude                               |
| 58  | weighted and phase-sensitive inversion recovery gradient echo high-resolution short                               |
| 159 | axis stacks, correlated with long axis LGE images, to grade presence, severity, and                               |
| 60  | location of scarring using the AHA 17-segment model. All clinical examinations were                               |

reviewed by two clinicians including an advanced cardiac imaging fellow, and advanced

162 cardiac imaging attending with Level-3 equivalent training.

163

164 Overview of AI model and training

For model training and testing, we used a convolutional neural network with residual 165 connections and spatiotemporal convolutions<sup>12</sup> to predict CMR findings, including the 166 presence of wall motion abnormalities, the presence of myocardial scar, native T1 value, 167 T2 value, and ECV fraction. For binary classification tasks for predicting dichotomized 168 CMR findings, we used binary cross-entropy loss and trained to maximize the area 169 under the receiver operating characteristics using an AdamW optimizer with an initial 170 learning rate of 0.001. For classification tasks including wall motion abnormalities, 171 172 scarring, abnormal T1, T2, and ECV, predictions were organized by presence or absence 173 abnormality within the AHA segments corresponding to the specific of 174 echocardiography view. To assess for the global presence or absence of any wall motion 175 abnormalities or myocardial scar, we combined the predictions for A4c, A2c, and PLAX views through logistic regression for a final prediction of these measurements. For a 176 regression tasks applied for prediction of continuous labels (native T1 value, T2 value, 177 178 and ECV fraction), the model was similarly trained in A4c, A2c, and PLAX views and 179 combined to provide a global result. The model was specified to minimize the mean 180 average error using squared loss. In both classification and regression tasks, early stopping with 10 epochs was applied, and the batch size and the number of epochs were 181 set to 10 and 50, respectively. The dataset was randomly split at an 8:1:1 ratio for model 182 training, validation, and held-out testing. The weights from the epoch with the best 183

metrics were used on the held-out test dataset. All model training and evaluation wereconducted using Python 3.8 and the publicly available PyTorch library.

186

187 <u>Statistical analysis</u>

All performance analyses were performed using a held-out test dataset not involved in 188 189 model training. For dichotomous outcomes, the model's ability was assessed by calculating the area under the receiver operating characteristic (AUROC) curve. For 190 continuous values including T1 value, T2 value, and ECV, mean absolute error (MAE) 191 and coefficient of determination (R<sup>2</sup>) were calculated. Bland-Altman plots where the 192 average of two measurements was plotted against the difference were used to check the 193 194 agreement between the actual and predicted values from echocardiography. 95% 195 confidence intervals were calculated with 10,000 bootstrapping samples. All data were analyzed using Python and R. 196

#### 198 **RESULTS**

199

### 200 Patient characteristics

We trained and tested a model using a dataset that included 2,556 echocardiography 201 202 studies paired with CMR findings from a total of 1,453 patients (mean age:  $56.0\pm17.9$ 203 years, 41.8% female). The patient population had a range of cardiovascular comorbidities including hypertension (37.7%), hyperlipidemia (28.5%), and diabetes 204 (16.5%) (Table 1). The mean left ventricular ejection fraction (LVEF) reported by 205 echocardiography and CMR was  $48.0\pm18.5\%$  and  $49.2\pm17.4\%$ , respectively. In the 206 CMR assessment, 48.3% had wall motion abnormalities and 49.0% had scar findings in 207 208 one or more of the AHA 17 segments. Mean native T1 value was  $1020 \pm 72.1$  ms with 26.0% of the patients having elevated values, mean T2 value was  $48.7 \pm 6.1$  ms with 209 8.2% having elevated values, and mean ECV was  $28.4 \pm 5.7\%$  with 21.8% having 210 211 elevated values. The median time interval between the echocardiography and CMR was 2 days (interquartile range, -2 to +6 days). 212

213

### 214 <u>Model Performance</u>

Prediction of wall motion abnormalities was robust, with the AUROC for prediction within the A4c segments of 0.817 (95% CI: 0.791-0.843), A2c of 0.756 (0.707-0.802) and PLAX of 0.812 (0.777-0.847). The combination of these view prediction for global wall motion abnormalities showed strong prediction, with AUROC of 0.873 (0.816-0.922) (**Figure 1**). On the other hand, prediction of tissue composition performed poorly overall. LGE prediction was low, at AUROC of 0.657 (0.620-0.693)

| 221 | in the A4c views and poor at AUROC of 0.591 (0.522-0.650) in the A2c view and 0.541    |
|-----|--|
| 222 | (0.483 - 0.594) in the PLAX views. The global prediction of 0.699 (0.613-0.780) was    |
| 223 | the highest (Figure 1). AUROC for prediction of T1, T2, and ECV was similarly limited, |
| 224 | with global prediction of abnormal T1 time of 0.614 (0.500-0.715), T2 time of 0.553    |
| 225 | (0.420-0.692), and ECV of 0.564 (0.455-0.691). These limited capabilities were         |
| 226 | consistent across A4c, A2c, and PLAX view videos (Table 2). Prediction of continuous   |
| 227 | measures globally showed that the models were minimally predictive, with $R^2$ of 0.04 |
| 228 | and MAE of 49.8 ms (47.5-52.2) for T1, $R^2$ of 0.002 and MAE of 5.39 ms (5.07-5.71)   |
| 229 | for T2 and $R^2$ of 0.07 and MAE of 4.38% (4.17-4.58) for ECV (Supplemental Figure     |
| 230 | 1).  |

#### 232 Discussion

233

In this study, we investigated the accuracy of a video-based deep learning model for 234 predicting CMR findings from echocardiography, with the express goal to bridge the 235 236 gap between the accessibility of echocardiography and the diagnostic information of 237 CMR. While the model was able to predict wall motion abnormalities, it was unable to reliably predict fundamental CMR tissue characteristics including LGE, T1, T2, and 238 ECV. Of these, the LGE prediction was the highest at 0.699 (0.613-0.780), which is 239 unlikely to be accurate enough for clinical utility. Overall, we would consider the 240 241 attempt to predict meaningful CMR tissue characteristics from echocardiography unsuccessful. 242

243

There has been limited previous cross-modality research specifically linking 244 245 echocardiography to CMR findings, with our literature review revealing no 246 deep-learning-based publications for LGE, let alone T1, T2, and ECV. A smaller study leveraging a radiomics-based approach in patients admitted for heart failure, was able to 247 identify the presence or absence of LGE in the anteroseptal and posterior wall 248 myocardial segments, within the specific regions where regions of interest were placed 249 250 for feature extraction. This was performed as a subset of a larger study, focusing on 89 251 patients for training and 40 patients for testing, all with echocardiography within 48 hours of clinical CMR, resulting in an AUROC of 0.84<sup>16</sup>. Other approaches such as 252 echocardiography speckle-tracking strain has also been used to predict LGE with 253 variable success – One publication demonstrated a significant association in 155 254 patients specifically diagnosed with carbon monoxide poisoning<sup>17</sup>, whereas a more 255

general and smaller 50-patient population was unable to find an association with 256 echo-based strain (AUROC of 0.58), but stronger associations with CMR-based strain 257 strain)<sup>18</sup>. (AUROC 0.67-0.78 including longitudinal and circumferential 258 Electrocardiogram (ECG) deep learning approaches have been applied to predict LGE 259 and appear to have potentially stronger associations than were found within our study, 260 261 though these are typically limited to specific populations. For example, prediction of LGE in patients with mitral valve prolapse using a CNN-based approach was able to 262 achieve an AUROC of 0.75 in approximately 600 patients<sup>19</sup>, and 0.76 in a hypertrophic 263 cardiomyopathy population of 1,930 patients though the AUROC decreased to 0.68 in 264 external validation<sup>20</sup>. A smaller study in 114 patients achieved AUROC up to 0.81 for 265 ECG prediction; however, this was from a 6-fold cross-validation without a hold-out 266 dataset, so there is likely a significant contribution of overfitting to the model<sup>21</sup>. 267

268

269 In reconciling our results with the established literature, we note that our population was 270 typically both larger, and more general than previous works. Inclusion of diverse clinical conditions may have reduced the ability to predict CMR tissue characteristics, 271 272 as the histological correlates of LGE, T1, T2, and ECV can vary between disease processes. However, our overarching motivation for echocardiographic tissue 273 274 characterization was broad accessibility independent of specific disease processes, and 275 therefore we felt that that this was the most appropriate approach. Additionally, given 276 that clinical echocardiography is already commonly used to accurately identify WMA, we present the strong deep learning prediction of WMA not as a proposed clinical 277 application, but to provide quality assurance for the workflow in mapping CMR labels 278 and echo images, and our ability to train deep learning models for echo. We also 279

recognize that of all of the tissue characterization markers, LGE was the highest and showed small signal for prediction (AUROC of 0.699); however, without a much stronger signal, we felt this was most likely due to prediction of confounding factors such as reduced ejection fraction or thinned myocardium. These factors may be easily visible on echocardiography and are associated with, but not equivalent to LGE; and thus not clinically useful to predict with deep learning.

286

Overall, the results of our study suggest that at least within the current population and 287 deep learning architecture, CMR-based tissue characteristics are unable to be derived 288 289 from standard clinical echocardiography at this time. Additional experiments testing prediction of deep learning across various sample size and model architectures had only 290 modest differences in performance (not shown). At the inception of this study, we 291 recognized that the ability to derive magnetic resonance-specific findings from an 292 293 ultrasound-based modality may have limited biological plausibility, as the image 294 acquisition and reconstruction process between the two modalities are extremely technically distinct. Historically however, echocardiography tissue characteristics such 295 as granular sparkling has been seen as suggestive of cardiac amyloidosis<sup>22</sup> and 296 integrated backscatter has been proposed for use within both inflammatory and fibrotic 297 conditions<sup>23,24</sup>. Detection of histological characteristics by echocardiography thus may 298 299 be best directly quantified, as while CMR-based tissue characterization is well-accepted, it still represents a surrogate of the true tissue composition. Novel echocardiography 300 techniques such as shear-wave elastography can provide signal for fibrosis not available 301 through standard clinical images and may be able to expand the applicability of 302 echocardiography independent of deep-learning based techniques<sup>25,26</sup>. Thus, while our 303

304 results support the ongoing utility for CMR independent of echocardiography, we are 305 optimistic for the future of echocardiography to provide highly accessible tissue 306 characterization.

307

308 Limitations

309 There are several limitations in the present study. First, as a retrospective single center study, our results were the result of a limited dataset. In particular, CMR practices may 310 vary significantly between locations, and it remains possible stronger relationships can 311 312 be found with larger datasets. The 30-day interval was selected as being a relatively short time frame but with a high number of eligible studies, and we recognize that 313 314 incident clinical events or resolution of acute findings may have occurred between the 315 two studies, though the short median time interval gives some degree of assurance. 316 CMR referral was clinical and included a wide range of diseases conditions and 317 severities. This heterogeneity may have increased the challenge of finding significant 318 associations.

# 320 Conclusion

In conclusion, we found that a video-based deep learning architecture using echocardiography was able to identify CMR-based WMA, but was unable to accurately identify CMR-based tissue characteristics including LGE, T1 time, T2 time, and ECV. Further testing using alternative populations and approaches should be considered. At present, our study supports the ongoing use of CMR for tissue characterization in appropriate patients, despite challenges to patient access.

329

- 331 ACK reports support from the American Heart Association (AHA; 23CDA1053659)
- and National Institutes of Health (NIH; UL1TR001881), and consulting fees from
- 333 InVision Medical Technology
- 334 DO reports support from the National Institute of Health (NIH; NHLBI R00HL157421)
- and Alexion, and consulting or honoraria for lectures from EchoIQ, Ultromics, Pfizer,
- InVision, the Korean Society of Echo, and the Japanese Society of Echo.
- 337

# 338 Sources of Funding

- 339 ACK: AHA 23CDA1053659, NIH UL1TR001881, 75N92020D00021
- 340 DO: NHLBI R00HL157421, 75N92020D00021
- 341 YS: Japanese Society for the Promotion of Science, Grants-in-Aid for Scientific
- 342 Research (JSPS-KAKENHI)

# 343 Author contributions

- 344 Concept and design: YS, DO, AK
- 345 Acquisition, analysis, or interpretation of data: YS, DO, AK, MV, GD, DB, SC
- 346 Drafting and Critical revision of the manuscript: All authors
- 347 Statistical analysis: YS, DO, AK
- 348 Obtained funding: DO, YS, AK
- 349 Supervision: AK, DO, SC, DB, DL
- 350 Data and code availability
- All of the code for the present study is available at https://github.com/echonet/.

## 353 Reference

| 355 | 1. | Lancellotti, P. et al. The use of echocardiography in acute cardiovascular care:    |
|-----|----|---|
| 356 |    | recommendations of the European Association of Cardiovascular Imaging and the       |
| 357 |    | Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 4, 3-5     |
| 358 |    | (2015).   |
| 359 | 2. | Omar, A. M. S., Bansal, M. & Sengupta, P. P. Advances in Echocardiographic          |
| 360 |    | Imaging in Heart Failure With Reduced and Preserved Ejection Fraction. Circ. Res.   |
| 361 |    | <b>119</b> , 357–374 (2016).  |
| 362 | 3. | Marwick, T. H., Neubauer, S. & Petersen, S. E. Use of cardiac magnetic resonance    |
| 363 |    | and echocardiography in population-based studies: why, where, and when? Circ.       |
| 364 |    | Cardiovasc. Imaging 6, 590–596 (2013).  |
| 365 | 4. | Goldfarb, J. W. & Weber, J. Trends in Cardiovascular MRI and CT in the U.S.         |
| 366 |    | Medicare Population from 2012 to 2017. Radiol Cardiothorac Imaging 3, e200112       |
| 367 |    | (2021).   |
| 368 | 5. | Poplin, R. et al. Prediction of cardiovascular risk factors from retinal fundus     |
| 369 |    | photographs via deep learning. Nat Biomed Eng 2, 158–164 (2018).                    |
| 370 | 6. | Holmstrom, L. et al. Deep learning-based electrocardiographic screening for         |
| 371 |    | chronic kidney disease. Commun. Med. 3, 73 (2023).                                  |
| 372 | 7. | Ouyang, D. et al. Electrocardiographic deep learning for predicting post-procedural |
| 373 |    | mortality: a model development and validation study. The Lancet Digital Health      |
| 374 |    | (2023) doi:10.1016/S2589-7500(23)00220-0.   |
| 375 | 8. | Attia, Z. I. et al. Age and Sex Estimation Using Artificial Intelligence From       |
| 376 |    | Standard 12-Lead ECGs. Circ. Arrhythm. Electrophysiol. 12, e007284 (2019).          |

- 9. Banerjee, I. et al. Reading Race: AI Recognises Patient's Racial Identity In Medical
- 378 Images. *arXiv* [*cs.CV*] (2021).
- 379 10. Ghorbani, A. *et al.* Deep learning interpretation of echocardiograms. *NPJ Digit*380 *Med* 3, 10 (2020).
- 11. Hughes, J. W. *et al.* Deep learning evaluation of biomarkers from echocardiogram
  videos. *EBioMedicine* 73, 103613 (2021).
- 383 12. Ouyang, D. *et al.* Video-based AI for beat-to-beat assessment of cardiac function.
  384 *Nature* 580, 252–256 (2020).
- 13. Schulz-Menger, J. *et al.* Standardized image interpretation and post-processing in
  cardiovascular magnetic resonance 2020 update : Society for Cardiovascular
  Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized
  Post-Processing. *J. Cardiovasc. Magn. Reson.* 22, 19 (2020).
- 14. Kawel-Boehm, N. *et al.* Reference ranges ("normal values") for cardiovascular
  magnetic resonance (CMR) in adults and children: 2020 update. *J. Cardiovasc. Magn. Reson.* 22, 87 (2020).
- 392 15. Cerqueira, M. D. et al. Standardized myocardial segmentation and nomenclature for
- 393 tomographic imaging of the heart. A statement for healthcare professionals from the
- Cardiac Imaging Committee of the Council on Clinical Cardiology of the American
  Heart Association. *Circulation* 105, 539–542 (2002).
- Kagiyama, N. *et al.* A low-cost texture-based pipeline for predicting myocardial
  tissue remodeling and fibrosis using cardiac ultrasound. *EBioMedicine* 54, 102726
  (2020).

399 17. Cho, D.-H. et al. Clinical and Echocardiographic Predictors for the Presence of

- 400 Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in
- 401 Patients with Carbon Monoxide Poisoning. *Diagnostics (Basel)* **14**, (2023).
- 402 18. Erley, J. et al. Echocardiography and cardiovascular magnetic resonance based
- 403 evaluation of myocardial strain and relationship with late gadolinium enhancement.
- 404 *J. Cardiovasc. Magn. Reson.* **21**, 46 (2019).
- 405 19. Tison, G. H. et al. Identifying Mitral Valve Prolapse at Risk for Arrhythmias and
- 406 Fibrosis From Electrocardiograms Using Deep Learning. *JACC Adv* **2**, (2023).
- 407 20. Carrick, R. T. et al. Identification of High-Risk Imaging Features in Hypertrophic
- Cardiomyopathy using Electrocardiography: A Deep-Learning Approach. *Heart Rhythm* (2024) doi:10.1016/j.hrthm.2024.01.031.
- 410 21. Gumpfer, N., Grün, D., Hannig, J., Keller, T. & Guckert, M. Detecting myocardial
  411 scar using electrocardiogram data and deep neural networks. *Biol. Chem.* 402, 911–
  412 923 (2021).
- 22. Cacciapuoti, F. The role of echocardiography in the non-invasive diagnosis of
  cardiac amyloidosis. *J. Echocardiogr.* 13, 84–89 (2015).
- 415 23. Hoyt, R. H., Collins, S. M., Skorton, D. J., Ericksen, E. E. & Conyers, D.
  416 Assessment of fibrosis in infarcted human hearts by analysis of ultrasonic
  417 backscatter. *Circulation* **71**, 740–744 (1985).
- 418 24. Omi, W. *et al.* Ultrasonic tissue characterization in acute myocarditis: a case report.
- 419 *Circ. J.* **66**, 416–418 (2002).
- 420 25. Caenen Annette *et al.* Ultrasound Shear Wave Elastography in Cardiology. *JACC*421 *Cardiovasc. Imaging* 17, 314–329 (2024).

# 422 26. Wouters, L. *et al.* Septal Scar Detection in Patients With Left Bundle Branch Block

- 423 Using Echocardiographic Shear Wave Elastography. *JACC Cardiovasc. Imaging* **16**,
- 424 713–715 (2023).

# 426 Figure Captions:

427 Graphical Abstract: Overview of the study pipeline and results. A large 428 echocardiography dataset involving 2,566 studies from 1,453 patients paired with CMR 429 and echocardiography within 30 days from Cedars-Sinai Medical Center was identified. 430 A convolutional neural network with residual connections and spatiotemporal 431 convolutions was trained to predict each CMR finding and detect abnormal findings 432 from echocardiography. Results showed strong prediction of functional abnormalities, 433 but poor prediction of CMR-specific tissue characterization.

Figure 1. Performance of deep-learning on a held-out test dataset. Receiver-operating-characteristic (ROC) curve for predicting myocardial wall motion abnormalities and myocardial scar finding detected by CMR. A: prediction of wall motion abnormalities, B: prediction of myocardial scar. Black curves denote the performance characteristics of a deep learning model for presence of global abnormal findings. Red, blue, and green curves demonstrated the prediction of abnormal findings within A4c, A2c, and PLAX views respectively.

# 441 Supplementary Figures

| 443 <b>abnormalities and estimation of CMR-specific tissue composition.</b> (A)444Receiver-operating-characteristic (ROC) curve for predicting abnormal CMR findings,445including native T1 value, T2 value, and extracellular volume fraction. Green curve446denotes the prediction of native T1 finding $\geq$ 1060ms. Purple denotes the prediction of447T2 $\geq$ 58ms. The orange curve denotes the prediction of ECV $\geq$ 33%. Scatterplot for448predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV. | 442 | Supplementary Figure 1: Performance of deep-learning model on prediction of                 |
|--|-----|---|
| Receiver-operating-characteristic (ROC) curve for predicting abnormal CMR findings,<br>including native T1 value, T2 value, and extracellular volume fraction. Green curve<br>denotes the prediction of native T1 finding $\geq$ 1060ms. Purple denotes the prediction of<br>T2 $\geq$ 58ms. The orange curve denotes the prediction of ECV $\geq$ 33%. Scatterplot for<br>predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV.   | 443 | abnormalities and estimation of CMR-specific tissue composition. (A)                        |
| including native T1 value, T2 value, and extracellular volume fraction. Green curve<br>denotes the prediction of native T1 finding $\geq$ 1060ms. Purple denotes the prediction of<br>T2 $\geq$ 58ms. The orange curve denotes the prediction of ECV $\geq$ 33%. Scatterplot for<br>predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV.  | 444 | Receiver-operating-characteristic (ROC) curve for predicting abnormal CMR findings,         |
| denotes the prediction of native T1 finding $\geq$ 1060ms. Purple denotes the prediction of<br>T2 $\geq$ 58ms. The orange curve denotes the prediction of ECV $\geq$ 33%. Scatterplot for<br>predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV.   | 445 | including native T1 value, T2 value, and extracellular volume fraction. Green curve         |
| 447 $T2 \ge 58ms$ . The orange curve denotes the prediction of ECV $\ge 33\%$ . Scatterplot for<br>448 predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV.   | 446 | denotes the prediction of native T1 finding $\geq$ 1060ms. Purple denotes the prediction of |
| predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV.  | 447 | T2 $\geq$ 58ms. The orange curve denotes the prediction of ECV $\geq$ 33%. Scatterplot for  |
|  | 448 | predicted versus measured (B) native T1 value, (C) T2 value, and (D) ECV.                   |

# 450 **<u>Tables</u>**

- 451 Table 1: Baseline patient characteristics, cardiac magnetic resonance and
- 452 echocardiogram findings

| Characteristic                                 | Unique Patients $(N = 1,453)^{T}$ |  |
|--|-----------------------------------|--|
| Age, mean (SD)                                 | 56.0 (17.9)                       |  |
| BMI  | 26.2 (8.6)                        |  |
| Gender, female                                 | 607.0 (41.8%)                     |  |
| Race/ethnicity                                 |                                   |  |
| American Indian                                | 8 (0.6%)                          |  |
| Asian  | 125 (8.6%)                        |  |
| Black  | 207 (14.2%)                       |  |
| Caucasian                                      | 973 (67.0%)                       |  |
| Other  | 140 (9.6%)                        |  |
| Hypertension                                   | 548 (37.7%)                       |  |
| Hyperlipidemia                                 | 414 (28.5%)                       |  |
| Diabetes                                       | 240 (16.5%)                       |  |
| CMR LVEF, mean (SD) (N=1,432)                  | 49.2 (17.4)                       |  |
| Native T1 (ms), mean (SD) (N=1,116)            | 1,020.7 (72.1)                    |  |
| T2 (ms), mean (SD) (N=1,069)                   | 48.7 (6.1)                        |  |
| ECV (%), mean (SD) (N=941)                     | 28.4 (5.7)                        |  |
| Native T1 >= 1060 ms                           | 290 (25.6%)                       |  |
| T2 >= 58 ms                                    | 88 (8.2%)                         |  |
| ECV >= 33%                                     | 205 (21.4%)                       |  |
| Global wall motion abnormality (CMR) (N=1,405) | 678 (48.3%)                       |  |

| Characteristic                               | Unique Patients $(N = 1,453)^{T}$ |  |
|--|-----------------------------------|--|
| Global scar finding (CMR) (N=1,252)          | 614 (49.0%)                       |  |
| Total Echocardiogram studies paired with CMR | 2,566 studies from 1,453 patients |  |
| Echocardiogram LVEF, mean (SD)               | 48.0 (18.5)                       |  |
| A4c videos                                   | 2,331 studies from 1,375 patients |  |
| A2c videos                                   | 1,965 studies from 1,270 patients |  |
| Plax videos                                  | 2,299 studies from 1,404 patients |  |

<sup>1</sup>Mean (SD); n (%)

453 CMR: Cardiac Magnetic Resonance; LVEF: Left Ventricular Ejection Fraction; BMI:

454 Body Mass Index; ECV: Extracellular Volume; SD: Standard Deviation;

455 **Table 2:** Diagnostic accuracy of deep learning for predicting wall motion abnormalities,

- 456 myocardial scar, and abnormal tissue composition by echocardiographic view
- 457

| Cardiac magnetic          |                                 |                        |
|---------------------------|---------------------------------|------------------------|
| resonance imaging         |                                 |                        |
| parameters                | Video                           | AUROC                  |
| Wall motion abnormalities |                                 |                        |
| WMA in A4c region         | A4c view                        | 0.817 (0.791 - 0.843)  |
| WMA in A2c region         | A2c view                        | 0.756 (0.707 - 0.802)  |
| WMA in PLAX region        | PLAX view                       | 0.812 ( 0.777 – 0.847) |
|                           | Logistic regression using three |                        |
|                           | views                           | 0.873 (0.816 - 0.922)  |
| Myocardial scar           |                                 |                        |
| Scar in A4c region        | A4c view                        | 0.657 (0.620 - 0.693)  |
| Scar in A2c region        | A2c view                        | 0.591 (0.522 - 0.650)  |
| Scar in PLAX region       | PLAX view                       | 0.541 (0.483 - 0.594)  |
|                           | Logistic regression using three |                        |
|                           | views                           | 0.699 (0.613 – 0.780)  |
| Relaxometry parameters    |                                 |                        |
| Native T1 value (ms)      | A4c view                        | 0.546 (0.497 - 0.596)  |
|                           | A2c view                        | 0.525 (0.479 - 0.581)  |
|                           | PLAX view                       | 0.518 (0.464 – 0.577)  |

|                  | Logistic regression using three |                       |
|------------------|---------------------------------|-----------------------|
|                  | views                           | 0.614 (0.500 - 0.715) |
| T2 value (ms)    | A4c view                        | 0.521 (0.465 - 0.578) |
|                  | A2c view                        | 0.539 (0.469 - 0.619) |
|                  | PLAX view                       | 0.559 (0.491 - 0.692) |
|                  | Logistic regression using three |                       |
|                  | views                           | 0.553 (0.420-0.692)   |
| ECV fraction (%) | A4c view                        | 0.549 (0.501 - 0.599) |
|                  | A2c view                        | 0.598 (0.514 - 0.680) |
|                  | PLAX view                       | 0.535 (0.463 - 0.691) |
|                  | Logistic regression using three |                       |
|                  | views                           | 0.564 (0.455 - 0.691) |

# 458 Figures:

### 459 Graphical Abstract:









# 462 **Supplementary Figure 1:**